Selective uptake of chitosan polymeric micelles by circulating monocytes for enhanced tumor targeting

Yang, Xiaofang; Lian, Keke; Tan, Yanan; Zhu, Yun; Li, Xuan; Zeng, Yingping; Yu, Tong; Meng, Tao; Yuan, Hong; Hu, Fuqiang

doi:10.1016/j.carbpol.2019.115435

Cited by 29 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Almost 94% of ; Schematic representation of a dendrimer (B) [38] ; Schematic representation of possible types of drug-dendrimer interactions (C) [38] ; Schematic representation of liposomes (left) versus polymersomes (right) (D) [47] the circulating monocytes took up the injected PM, which was visualized with the help of fluorescent molecules. Then, it was exocytosed by macrophages and taken up by 4T1 cancer cells, which shows the efficacy of the treatment method [34] .…”

Section: Polymeric Micellesmentioning

confidence: 94%

See 1 more Smart Citation

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Benko¹

2020

CDR

View full text Add to dashboard Cite

Cancer is one of the biggest healthcare concerns in our century, a disease whose treatment has become even more difficult following reports of drug-resistant tumors. When this happens, chemotherapy treatments fail or decrease in efficiency, leading to catastrophic consequences to the patient. This discovery, along with the fact that drug resistance limits the efficacy of current treatments, has led to a new wave of discovery for new methods of treatment. The use of nanomedicine has been widely studied in current years as a way to effectively fight drug resistance in cancer. Research in the area of cancer nanotechnology over the past decades has led to tremendous advancement in the synthesis of tailored nanoparticles with targeting ligands that can successfully attach to chemotherapy-resistant cancer by preferentially accumulating within the tumor region through means of active and passive targeting. Consequently, these approaches can reduce the off-target accumulation of their payload and lead to reduced cytotoxicity and better targeting. This review explores some categories of nanocarriers that have been used in the treatment of drug-resistant cancers, including polymeric, viral, lipid-based, metal-based, carbon-based, and magnetic nanocarriers, opening the door for an exciting field of discovery that holds tremendous promise in the treatment of these tumors.

show abstract

Section: Polymeric Micellesmentioning

confidence: 94%

“…Almost 94% of the circulating monocytes took up the injected PM, which was visualized with the help of fluorescent molecules. Then, it was exocytosed by macrophages and taken up by 4T1 cancer cells, which shows the efficacy of the treatment method [ 34 ] .…”

Section: Nanocarriers For the Treatment Of Drug Resistance In Tumorsmentioning

confidence: 99%

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Benko¹

2020

CDR

View full text Add to dashboard Cite

show abstract

“…However, by targeting circulating monocytes, its natural phagocytic properties can be harnessed for nanoparticle loading, with the idea that upon homing to the tumor site, they can differentiate into macrophages and serve as "Trojan Horses" to release their cargo deep within the hypoxic tumor in a controlled manner [23]. For example, Yang et al [102] used live circulating monocytes to hitchhike a docetaxel-loaded polymeric-micelle formulation synthesized from chitosan and stearic acid. The authors chose chitosan for its biocompatible and biodegradable properties and stearic acid for its cell membrane compatibility that promotes cell uptake.…”

Section: Cellular Hitchhiking With Macrophagesmentioning

confidence: 99%

Approaches to Improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the Enhanced Permeability and Retention Effect

et al. 2022

View full text Add to dashboard Cite

Passive targeting is the foremost mechanism by which nanocarriers and drug-bearing macromolecules deliver their payload selectively to solid tumors. An important driver of passive targeting is the enhanced permeability and retention (EPR) effect, which is the cornerstone of most carrier-based tumor-targeted drug delivery efforts. Despite the huge number of publications showcasing successes in preclinical animal models, translation to the clinic has been poor, with only a few nano-based drugs currently being used for the treatment of cancers. Several barriers and factors have been adduced for the low delivery efficiency to solid tumors and poor clinical translation, including the characteristics of the nanocarriers and macromolecules, vascular and physiological barriers, the heterogeneity of tumor blood supply which affects the homogenous distribution of nanocarriers within tumors, and the transport and penetration depth of macromolecules and nanoparticles in the tumor matrix. To address the challenges associated with poor tumor targeting and therapeutic efficacy in humans, the identified barriers that affect the efficiency of the enhanced permeability and retention (EPR) effect for macromolecular therapeutics and nanoparticle delivery systems need to be overcome. In this review, approaches to facilitate improved EPR delivery outcomes and the clinical translation of novel macromolecular therapeutics and nanoparticle drug delivery systems are discussed.

show abstract

“…This high selectivity of SWNT uptake by the Ly-6C hi subset instead of the EPR effect is probably much more beneficial for treating solid tumors. Similarly, Yang et al reported that COSA micelles, composed of chitosan and stearic acid, were selectively taken up by circulating Ly-6C hi monocytes in a receptor-mediated way after intravenous administration [ 110 ]. It is difficult for injected particles to reach deep hypoxic regions given the lack of vessels in solid tumors; targeting Ly-6C hi monocytes in the blood for drug delivery may overcome this limitation.…”

Section: Mammalian Cell-based Ddssmentioning

confidence: 99%

Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy

Jin

2022

Pharmaceutics

View full text Add to dashboard Cite

Undesirable side effects and multidrug resistance are the major obstacles in conventional chemotherapy towards cancers. Nanomedicines provide alternative strategies for tumor-targeted therapy due to their inherent properties, such as nanoscale size and tunable surface features. However, the applications of nanomedicines are hampered in vivo due to intrinsic disadvantages, such as poor abilities to cross biological barriers and unexpected off-target effects. Fortunately, biomimetic nanomedicines are emerging as promising therapeutics to maximize anti-tumor efficacy with minimal adverse effects due to their good biocompatibility and high accumulation abilities. These bioengineered agents incorporate both the physicochemical properties of diverse functional materials and the advantages of biological materials to achieve desired purposes, such as prolonged circulation time, specific targeting of tumor cells, and immune modulation. Among biological materials, mammalian cells (such as red blood cells, macrophages, monocytes, and neutrophils) and pathogens (such as viruses, bacteria, and fungi) are the functional components most often used to confer synthetic nanoparticles with the complex functionalities necessary for effective nano-biointeractions. In this review, we focus on recent advances in the development of bioinspired and biomimetic nanomedicines (such as mammalian cell-based drug delivery systems and pathogen-based nanoparticles) for targeted cancer therapy. We also discuss the biological influences and limitations of synthetic materials on the therapeutic effects and targeted efficacies of various nanomedicines.

show abstract

Selective uptake of chitosan polymeric micelles by circulating monocytes for enhanced tumor targeting

Cited by 29 publications

References 31 publications

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Approaches to Improve Macromolecule and Nanoparticle Accumulation in the Tumor Microenvironment by the Enhanced Permeability and Retention Effect

Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy

Contact Info

Product

Resources

About